CASI Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $7,793 | $3,979 | $3,409 | $6,091 |
Gross Profit | 4,045 | 2,067 | 1,806 | 3,819 |
EBITDA | -8,085 | -12,180 | -8,284 | -2,523 |
EBIT | -8,464 | -8,789 | -9,220 | -3,459 |
Net Income | -8,395 | -6,965 | -9,528 | -5,461 |
Net Change In Cash | 7,793 | 3,979 | 3,409 | 6,091 |
Cash | 16,537 | 9,533 | 12,201 | 17,083 |
Basic Shares | 15,294 | 13,519 | 13,382 | 13,378 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $33,879 | $43,107 | $30,168 | $15,141 |
Gross Profit | 20,052 | 27,280 | 17,611 | 5,633 |
EBITDA | -21,539 | -24,069 | -32,747 | -31,354 |
EBIT | -25,280 | -26,491 | -35,842 | -34,585 |
Net Income | -26,938 | -39,411 | -37,772 | -62,567 |
Net Change In Cash | 33,879 | 43,107 | 30,168 | 15,141 |
Cost of Revenue | -18,360 | |||
Free Cash Flow | -22,208 | -26,700 | -42,342 | -45,213 |
Cash | 17,083 | 47,112 | 38,704 | 57,064 |
Basic Shares | 13,360 | 13,647 | 13,610 | 11,045 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.54 |
2024-06-30 | -$0.55 |
2024-03-31 | -$0.71 |
2023-12-31 | -$0.45 |
